Related Experiment Videos
[Multimodality therapy concepts in esophageal carcinoma]
1Chirurgische Klinik, Technische Universität München, Ismaningerstrasse 22, 81675 München.
Kongressband. Deutsche Gesellschaft Fur Chirurgie. Kongress
|February 5, 2002
Summary
Preoperative chemotherapy for esophageal cancer shows survival benefits in responders. Developing a diagnostic test to predict response is crucial for tailoring treatment and improving outcomes in esophageal cancer patients.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Context:
- The efficacy of preoperative chemotherapy for esophageal cancer remains debated.
- Limited randomized controlled trials show survival benefits with neoadjuvant chemotherapy.
- Patient response to preoperative therapy correlates with significantly prolonged survival.
Purpose:
- To highlight the critical need for predictive response markers in esophageal cancer.
- To emphasize the importance of identifying responders for neoadjuvant chemotherapy.
- To guide treatment decisions in potentially resectable esophageal cancer.
Summary:
- Preoperative chemotherapy's role in esophageal cancer is controversial, with survival benefits observed mainly in responders.
- Currently, no established molecular markers or non-invasive techniques like FDG-PET reliably predict response.
- Responders are candidates for esophagectomy, while non-responders may receive salvage therapy.
Impact:
- Establishes the necessity for diagnostic tests to personalize neoadjuvant chemotherapy in esophageal cancer.
- Aims to optimize treatment strategies by differentiating responders from non-responders.
- Potential to improve survival rates and treatment efficacy for esophageal cancer patients.